CAMBRIDGE, MA - September 16, 2015 - Aurora BioPharma, Inc. announces its participation at the Redefining Early Stage Investments (RESI) Boston 2015 conference. The event will be held at The Westin Copley Place in Boston, MA, on September 16, 2015. Life Science Nation (LSN) will be hosting the gathering in collaboration with Johnson & Johnson Innovation, JLABS (JLABS). The RESI conference attracts Corporate Venture Capital Funds, Family Offices, Venture Philanthropy Funds, VCs, and Angel groups. The event serves as an opportunity for fundraising executives to identify and meet life science investors. The goal is to develop new medical breakthroughs in the discovery of advanced technologies and cancer immunotherapies.
Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes Chimeric Antigen Receptor T-cell therapy (CAR T) with a completed Phase 1 trial in the solid tumors of Glioblastoma and Sarcoma. In Glioblastoma brain cancer, its CAR T drug AU-105 achieved its endpoint of safety and significant survival benefit of 24.8 median overall survival. Aurora's team is comprised of experienced research scientists and business professionals with successful track records in the industry.
The company also has an equity interest in MedVax Technologies, Inc. that has the following two cancer vaccines: MX-225, an autologous Adenovirus P53 dendritic cell vaccine that has completed two FDA Phase II clinical trials, in Small Cell Lung Cancer, and the company is planning a combination trial with a PD-1 antibody in lung cancer in collaboration with a major pharmaceutical company. MX-225 is also in a Phase II combination trial in breast cancer with indoximod, an IDO inhibitor from NewLink Genetics. And MX-402, a HER2 Peptide vaccine that in a Phase I trial in solid tumors had reported 8 of 12 patients having a clinical benefit.
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that serves as the gathering for early stage life sciences companies. The gatherings provide an opportunity for executives to collaborate with investors, develop relationships, and create new funding opportunities. The attendees will have the chance to participate in an array of discussion panels and workshops held by investors with a particular focus on the healthcare sector.
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Candace Cobos
VP, Business Development & Public Relations
Harvard Square, One Mifflin Place, Suite 400
Cambridge, MA 02138
Tel: (617) 674-7718 - Fax: (617) 674-7701
Ingraham Building, 25 SE 2nd Avenue, Suite 504
Miami, FL 33131
Tel: (305) 371-2301 - Fax: (305) 371-2304
candace.cobos@aurorabiopharma.net - www.aurorabiopharma.net
New Paradigm in Cancer Immunotherapy
Source: Aurora BioPharma, Inc.